Amneal raises 2026 guidance again, reprices term loan, moves ahead on Kashiv deal

Amneal Pharmaceuticals reported second quarter 2026 results on July 30, 2026, raising its full-year guidance for the second time this year. Company leadership said the robust first-half performance gave them confidence to raise full-year 2026 guidance for the second time this year.¹

Updated 2026 guidance calls for net revenue of $3.10 billion to $3.20 billion, up from a prior range of $3.05 billion to $3.15 billion, with adjusted EBITDA guidance moved to $750 million to $780 million from $740 million to $770 million, and adjusted diluted EPS guidance of $0.96 to $1.06, up from $0.95 to $1.05. Operating cash flow guidance was held at $350 million to $400 million, while capital expenditure guidance rose to approximately $150 million from approximately $110 million.¹

On financing, the company in July 2026 launched a repricing of its $2.084 billion Term Loan B, cutting the rate by 50 basis points from SOFR plus 300 basis points to SOFR plus 250 basis points, with the repricing expected to close as early as August 3, 2026.¹ Amneal also intends to obtain an additional $350 million Term Loan B financing to fund part of the Kashiv BioSciences purchase price, with the new loans set to be drawn when the Kashiv acquisition closes, at the same reduced pricing.¹ The repricing is expected to generate about $12 million in annual cash interest savings and support the company's goal of cutting net leverage below 3.0x by 2028.¹

On the pending acquisition, management said the Kashiv transaction would establish biosimilars as a new, durable growth vertical for Amneal, further diversifying its portfolio.¹ The release did not give a specific expected closing date for the Kashiv deal beyond tying it to the term loan financing timeline.